Stockwinners Market Radar for December 06, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:47 EST Golden Minerals to be delisted from NYSE - Golden Minerals announced that it has received notification from the NYSE that the exchange determined to commence proceedings to suspend and delist the company's common stock as a result of its determination that the Company is no longer suitable for listing due to its non-compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide, which require the company to report stockholders' equity of $6M or more if the company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, as previously reported. The company anticipates that the common stock will begin trading on the OTC Pink Market at the open of business on December 16.

17:34 EST Owens & Minor awarded $4.5B Defense Logistics Agency contract modification - Owens and Minor Distribution has been awarded a maximum $4.5B modification exercising the third 30-month option period of a 30-month base contract with three 30-month option periods. This is a firm-fixed-price, indefinite-delivery/indefinite-quantity contract for worldwide ordering and distribution of consumable, commercial, brand name and generic medical surgical supplies in support of the medical surgical prime vendor Generation V program. Locations of performance are throughout the continental U.S., with a June 6, 2027, performance completion date. Using customers are Air Force, Army, Navy, Marine Corps, Coast Guard and federal civilian agencies. Type of appropriation is fiscal 2025 through 2027 defense working capital funds. defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support.

17:33 EST Terreno Realty to replace Hudson Pacific in S&P 600 at open on 12/23 - S&P Dow Jones Indices is making the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance.

17:32 EST Carter's to replace Carpenter Technology in S&P 600 at open on 12/23 - S&P Dow Jones Indices is making the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance.

17:30 EST Carpenter Technology to replace Carter's in S&P 400 at open on 12/23 - S&P Dow Jones Indices is making the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance.

17:28 EST Carpenter Technology to replace Carter's in S&P 600 at open on 12/23 - S&P Dow Jones Indices is making the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance.

17:26 EST Amentum to replace Service Properties in S&P 600 at open on 12/23 - S&P Dow Jones Indices is making the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance.

17:23 EST Workday to replace Amentum in S&P 500 at open on 12/23 - S&P Dow Jones Indices is making the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance.

17:17 EST Tandy Leather to sell corporate headquarters for $26.5M - Tandy Leather announced that it had signed a purchase and sale agreement to sell its corporate headquarters facilities, including its primary distribution center and flagship retail store, to Colonna Brothers. The sale price for the facilities, before taxes and expenses, will be $26.5M, and the transaction is expected to close in January 2025. Upon the closing, the company intends to enter into lease agreements to remain in its current spaces until approximately September 2025, while it identifies and prepares to move to new facilities in the Fort Worth, Texas area.

17:06 EST AES Corp. increases quarterly dividend 2% to 17.595 per share - The board of directors of AES Corp. approved an increase of 2% in the company's quarterly common stock dividend, from 17.25c per share to 17.595 per share, beginning in the first quarter of 2025.

17:00 EST BIOAGE Labs Inc trading resumes

16:37 EST BioAge Labs discontinues STRIDES phase 2 clinical trial - BioAge Labs announced that the company has made the decision to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag as monotherapy and in combination with tirzepatide after liver transaminitis without clinically significant symptoms was observed in some subjects receiving azelaprag. No transaminase elevations were observed in the tirzepatide only treatment group. "Patient safety is our top priority in the conduct of our clinical studies," said Kristen Fortney, PhD, CEO and co-founder of BioAge. "We made the difficult decision to discontinue the STRIDES Phase 2 study of azelaprag because it became clear that the emerging safety profile of the current doses tested is not consistent with our goal of a best-in-class oral obesity therapy. While this outcome is a significant disappointment, we remain encouraged by azelaprag's promising preclinical and Ph1b efficacy profile. We remain committed to our focus on developing therapies for metabolic aging. In parallel to assessing the next steps for the azelaprag program, we will continue to advance our NLRP3 inhibitor program as well as additional research programs with novel mechanisms emerging from our platform."

16:18 EST W. R. Berkley announces 50c per share special cash dividend - W. R. Berkley announced that its board of directors declared a special cash dividend on its common stock of 50c per share to be paid on December 27 to stockholders of record at the close of business on December 16. The special dividend announced is the third in 2024.

16:16 EST Morningstar raises quarterly dividend 12.3% to 45.5c per share - The board of directors of Morningstar declared a quarterly dividend of 45.5c per share, payable Jan. 31, 2025, to shareholders of record as of Jan. 3, 2025. The five-cent, or 12.3%, increase from the prior quarterly rate of 40.5 cents per share results in an expected annualized dividend of $1.82 per share compared with the prior annualized rate of $1.62 per share.

16:06 EST Alpha Metallurgical chairman Stetson to leave company - Alpha Metallurgical Resources announced the retirement of chairman David Stetson from its board of directors, effective December 13, 2024. Stetson's departure, which is not a result of any disagreement with the company, comes after his significant and successful tenure with Alpha during which the company paid off its long-term debt and posted record revenue generation. Concurrent with Stetson's departure, lead independent director Michael Gorzynski will assume the role of chairman of the board. Earlier today, Alpha's board approved Gorzynski's appointment as chairman, as well as a decrease in the board's size from seven to six members, effective December 13, 2024.

16:00 EST BIOAGE Labs Inc trading halted, news pending

15:29 EST GE Aerospace says it is positioned to deliver continued growth in 2025 - GE Aerospace released a letter providing updates on the company's "busy" fourth quarter. Of note, the company said it is positioned to deliver continued revenue, profit, and free cash flow growth in 2025. In CES, services is expected to be up low-double-digits from significant backlog of shop visit demand, LEAP services growth, mature fleets flying longer, and pricing. Both internal shop visits and spare parts will contribute to our growth, with spare part sales expected to be in-line with overall services growth. "We expect that OE will grow faster than services, including LEAP output up 15-20% aligned with Safran's comments yesterday," said GE Aerospace. "We also continue to expect LEAP program will achieve breakeven next year and will no longer be a headwind to GE Aerospace margins. We continue to work through our expectations for 9X, but we expect shipments to grow. In DPT, we continue to expect revenue grows MSD/HSD and profit grows faster than revenue. We look forward to providing further color on our 2025 guidance at our earnings call in January." Reference Link

14:01 EST Graco raises quarterly dividend 7.8% to 27.5c per share - The board of directors of Graco has declared a regular quarterly dividend of 27.5c per common share, an increase of 7.8%, payable on February 5 to shareholders of record at the close of business on January 20.

13:13 EST EU approves Novo Holdings' acquisition of Catalent - The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of Catalent (CTLT) by Novo Holdings. The Commission concluded that the transaction would not raise competition concerns in the European Economic Area. Novo Holdings is the ultimate owner of Novo Nordisk (NVO). The Commission concluded that the proposed merger would not raise competition concerns on any of the markets examined in the EEA or on any substantial part of it. It therefore cleared the transaction unconditionally.

13:07 EST Credit Agricole seeks approval to boost Banco BPM stake - Credit Agricole (CRARY) said it notified the Italian Authority and Banco BPM (BNZCF) that it has entered into financial instruments relating to 5.2% of Banco BPM share capital, which can be physically settled subject to regulatory approvals. Considering the stake of 9.9% already held, the resulting aggregate position in Banco BPM notified by Credit Agricole amounts to 15.1%. Credit Agricole is going to apply for the supervisory authority's authorization to increase its stake in Banco BPM's share capital above 10% and up to 19.99%.

13:00 EST Baker Hughes reports U.S. rig count up 7 to 589 rigs

12:04 EST Rapport Therapeutics presents data on long episode seizure biomarker - Rapport Therapeutics announced it will present "novel findings" on the association between a seizure biomarker used in the company's proof-of-concept trial for RAP-219 and clinical seizures. The analysis demonstrated a linear relationship between changes in long episode frequency and clinical seizure frequency and identified the benchmark to predict clinically meaningful seizure reduction. Rapport is presenting the data at the American Epilepsy Society Annual Meeting in Los Angeles, December 6-10, the company stated. "We believe these findings establish a new benchmark for evaluating the potential efficacy of RAP-219 and other anti-seizure medications, providing a consistent metric to help inform the development of future treatments," the company stated. Added Dr. Brad Galer, Chief Medical Officer of Rapport Therapeutics: "The long episode seizure biomarker provides a potentially transformative approach to evaluating the efficacy of anti-seizure medications. These new data reveal a clear, linear relationship between long episode and clinical seizure frequencies. We look forward to advancing our research of RAP-219 using this novel biomarker in our proof-of-concept trial, enabling a more precise and expedited development path to hopefully deliver a new potential antiseizure medication for refractory focal epilepsy patients."

Tilly's is down -8.7%, or -38c to $4.00.

Unisys is down -18.3%, or -$1.63 to $7.29.

Rubrik is up 33.6%, or $18.05 to $71.71.

11:57 EST Oshkosh down 5% after Reuters says Trump may nix USPS deal - Ford (F), which also has a deal to supply EVs for the United States Postal Service, is fractionally higher near midday following Reuters' report.

11:38 EST Square Enix's 'Dragon Quest III' remake sells 2M units - Square Enix (SQNXF) said its recent game "Dragon Quest III HD-2D Remake" has shipped and downloaded 2M units since its release in mid-November. The game is available on PC, PlayStation 5 (SONY), Xbox Series X/S (MSFT), and Nintendo Switch (NTDOY). Reference Link

11:30 EST Senator Lee asks FTC to investigate online gambling companies over anti-trust - Senator Mike Lee of Utah stated in a post to X: "We can't allow online gambling companies like @FanDuel & @DraftKings to violate anti-trust laws, especially as more Americans grapple with the effects of this industry on our society. Glad to join @SenPeterWelch requesting that @linakhanFTC investigate and protect consumers." Flutter Entertainment is the parent company of FanDuel. Reference Link

10:52 EST ZJK Industrial Co Ltd trading halted, volatility trading pause

BigBear.ai is up 12.9%, or 37c to $3.23.

Asana is up 38.9%, or $6.01 to $21.47.

Unisys is down -14.5%, or -$1.29 to $7.63.

09:50 EST Profound Medical trading resumes

SOS Limited is down -7.8%, or -69c to $8.15.

Unisys is down -10.9%, or -97c to $7.95.

Rubrik is up 18.8%, or $10.07 to $63.73.

09:44 EST RADX Stock trading resumes

09:38 EST zSpace, Inc. trading resumes

09:33 EST zSpace, Inc. trading halted, volatility trading pause

09:30 EST Oriental Rise Holdings Ltd trading halted, volatility trading pause

09:30 EST Cero Therapeutics appoints Chris Ehrlich as CEO - Cero Therapeutics (CERO) announced its board of directors has appointed Chris Ehrlich as CEO. Previously he held the position of interim CEO. In addition to his role at Cero, he currently serves as CEO of Launch One Acquisition Corporation (LPAA).

09:19 EST Terreno Realty acquires industrial property in New York for $7.6M - Terreno Realty acquired an industrial property located in Long Island City Queens, New York for a purchase price of approximately $7.6M. The property consists of one industrial distribution building containing approximately 17,000 square feet on 0.4 acres. The property is at 48-29 31st Place, adjacent to I-495 approximately one mile from the Queens Midtown Tunnel, provides one dock-high, one van-level and one grade-level loading positions and parking for seven cars. The property is vacant and the estimated stabilized cap rate is 5.7%.

09:10 EST Profound Medical trading halted, news pending

09:08 EST Golden Matrix issues update from CEO Brian Goodman - Golden Matrix issued a corporate update from CEO Brian Goodman highlighting the Company's recent performance, strategic priorities and financial positioning. The company said, "As recently announced, Golden Matrix Group is nearing formal approval for entry into Brazil's regulated market, completing another step in the process of becoming one of the first companies to receive a license to operate in the country in accordance with new regulations. Licenses for brands that meet the correct requirements are expected to be granted by the end of this year. Brazil's regulated online sports betting and iGaming market is projected to reach $5.6 billion Gross Gaming Revenue (GGR) by 2025, according toH2GC, an extraordinary growth opportunity that Golden Matrix is well-positioned to capture. As of September 30, 2024, the Company reported $38.4 million in cash reserves, significantly exceeding its $17.5 million in short-term debt. This strong balance sheet enables liability management, supports accretive acquisitions and empowers the execution of GMGI's growth strategy. The Company has taken prudent steps to enhance liquidity and provide flexibility in its capital sourcing strategy. The recent filing of an At-The-Market (ATM) offering is a standard financial tool that reinforces the Company's long-term positioning."

09:04 EST Earlyworks enters business alliance agreement with Service Innovation - Earlyworks has entered into a business alliance agreement with Service Innovation, the operator of the gourmet website "Yummeet!" "This partnership aims to integrate our blockchain technology with the expertise of Service Innovation in operating a gourmet website to record reviews and ratings in an immutable format, enhancing transparency and trust. Many existing gourmet platforms adopt an advertising revenue model, leading to frequent manipulation and inaccurate postings of reviews and ratings. Consequently, users often struggle to obtain reliable information. Our blockchain technology serves as a critical foundation to address these challenges. By leveraging blockchain, reviews and rating data can be stored without risk of tampering or deletion, ensuring users have access to trustworthy information. This creates an environment where users can more easily find dining establishments that match their preferences. We aim to establish a new 'user-first' standard in the gourmet website domain, delivering innovative value creation."

09:02 EST Cero Therapeutics names Chris Ehrlich as CEO - CERo Therapeutics announces its Board of Directors has appointed Chris Ehrlich as CEO. Previously he held the position of Interim CEO.

08:52 EST NewtekOne forecasts about $1.4B in business loans in 2024 - NewtekOne announced that it reaffirmed its forecast to originate approximately $1.4B in business loans in 2024 across all of its loan products including SBA 7(a) loans, SBA 504 loans, alternative loan program loans, CRE conforming loans, and C&I conforming loans. The Company forecasts originating approximately $1.9B in business loans across all its loan products in 2025, which would represent an approximate 36% increase over its expectations for the 2024 total business loan origination. Most of the 2025 loan origination growth is expected from the alternative loan program, CRE conforming loans, C&I conforming loans, and SBA 504 loans. It is important to note that in the second quarter 2023, the company ceased originating its SBA 7(a) loans at Newtek Small Business Finance, the company's non-bank lender, and since that time all SBA 7(a) loans have been originated by Newtek Bank, N.A. As a result, the actual growth in SBA 7(a) originations should be viewed as growth on a historical consolidated basis rather than just at Newtek Bank, N.A.

08:32 EST Icahn Enterprises commences tender offer for 17.75M CVR Energy shares - Icahn Enterprises (IEP) and Icahn Enterprises Holdings L.P. announced the commencement of a cash tender offer for up to 17,753,322 shares of CVR Energy's (CVI) common stock at a price per share of $18.25, representing a premium of approximately 10.5% to the closing price of $16.52 per share on November 7, the last full trading day completed prior to the receipt and public disclosure of a letter IEP sent to the CVR Energy Board of Directors proposing a potential tender offer. IEH is the beneficial owner of approximately 66% of the outstanding shares of CVR Energy common stock and, if the tender offer is fully or over-subscribed, would become the beneficial owner of approximately 84% of the outstanding shares of CVR Energy common stock. The tender offer is scheduled to expire at one minute after 11:59 P.M., New York City time, on January 6, 2025, unless the offer is extended.

08:09 EST PDS Biotechnology reports inducement grant under Nasdaq listing rule - PDS Biotechnology announced that on December 3, 2024, PDS Biotech granted nonstatutory stock options to purchase 7,000 shares of common stock to an employee in the clinical department as a material inducement to employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635(c)(4) and PDS Biotech's 2019 Inducement Plan, as amended, which was adopted on June 17, 2019, and provides for the granting of equity awards to new employees of PDS Biotech. Each stock option has an exercise price of $2.25, the closing price of PDS Biotech's common stock on December 3, 2024. Each stock option vests over a four-year period, with one-quarter of the shares vesting on the first anniversary of the grant date and the remaining shares vesting monthly over the 36-month period thereafter, subject to continued employment with the company through the applicable vesting dates.

08:08 EST Pacira reports inducement grants under Nasdaq listing rule - Pacira BioSciences announced the granting of inducement awards on December 3, 2024 to four new employees under Pacira's Amended and Restated 2014 Inducement Plan as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the Compensation Committee of the Board of Directors. Four employees received stock options to purchase an aggregate of 19,800 shares of Pacira common stock and the four employees received restricted stock units for an aggregate of 23,600 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient's first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $16.68 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on the first anniversary of December 1, 2024. Vesting of the equity awards is subject to the employee's continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

08:06 EST Verrica announces development partner Torii files NDA for TO-208 in Japan - Verrica Pharmaceuticals announced its development and commercialization partner, Torii Pharmaceutical, submitted a New Drug Application of TO-208 for the treatment of Molluscum Contagiosum in Japan. TO-208 is a skin disease treatment drug candidate containing cantharidin as an active ingredient. In the Phase 3 clinical study of TO-208 in patients with molluscum contagiosum in Japan, the primary endpoint of efficacy has met superiority to the vehicle. Furthermore, the safety profile of TO-208 in the study was consistent to prior studies in the United States and there were no observed issues of tolerability for the application. Torii and Verrica executed an exclusive license agreement for the development and commercialization of TO-208 for the treatment of molluscum and common warts in Japan in March 2021. Verrica received manufacturing and marketing approval of VP-102 to treat molluscum contagiosum in the U.S. in July 2023. Verrica has marketed VP-102 under the brand name YCANTH in the U.S. since August 2023 and has completed a Phase 2 clinical study of VP-102 for the treatment of common warts and a Phase 2 clinical study of VP-102 for the treatment of external genital warts in the U.S.

07:47 EST European Residential REIT files information circular for special meeting - European Residential Real Estate Investment Trust has filed its notice-and-access notification, management information circular, form of proxy and voting instruction form in respect of its previously announced special meeting of the holders of trust units of the REIT and non-participating special voting units of the REIT to approve certain amendments to its declaration of trust. The Meeting is scheduled to be held in a virtual only meeting format via live webcast online at 10:00 a.m. on January 7, 2025. In light of the ongoing Canada Post labour disruption, ERES has couriered to registered Unitholders a notice-and-access notification with respect to the Information Circular and a form of proxy.

07:34 EST Mattr Corp. announces pricing of debt subscription receipts - Mattr Corp. has entered into an underwriting agreement to sell, pursuant to a private placement offering, 125,000 debt subscription receipts at a price of $1,018.75 per Subscription Receipt, plus accrued but unpaid interest on the underlying Note from October 2, 2024 to, but excluding the closing of the Offering, for an aggregate issue price of $1,034 and gross proceeds to the Company of approximately $129.3 million. Each Subscription Receipt will entitle the holder thereof to receive, upon the satisfaction of certain conditions and without payment of additional consideration or further action, a newly authenticated 7.25% senior unsecured note of the Company due April 2, 2031, in a principal amount of $1,000. The Notes shall be issued as "Additional Notes" pursuant to the trust indenture dated April 2, 2024 between TSX Trust Company and the Company, as supplemented by a supplemental indenture, such that, following the issuance thereof, $300 million aggregate principal amount of 7.25% senior unsecured notes of the Company due April 2, 2031, will be outstanding. Mattr intends to use the net proceeds of the Offering to pay a portion of the purchase price for the Company's previously announced indirect acquisition of all of the issued and outstanding shares of AmerCable. Mattr expects the closing of the Acquisition to occur in the first quarter of 2025. The Subscription Receipts are being offered through TD Securities and National Bank Financial Markets.

07:33 EST SL Green Realty board raises annual dividend 3% to $3.09 per share - SL Green Realty board of directors has established an annual ordinary dividend on SL Green's common stock for 2025 of $3.09 per share, an increase of 3.0%. The ordinary dividend will continue to be paid in cash on a monthly basis. The first monthly ordinary dividend of $0.2575 per share is payable on January 15, 2025, to stockholders of record at the close of business on December 31, 2024. The board of directors also declared the regular quarterly dividend on the company's Series I Preferred Stock for the period October 15, 2024 through January 14, 2025 of $0.40625 per share, which is the equivalent of an annualized dividend of $1.625 per share. The dividend is payable in cash on January 15, 2025 to shareholders of record at the close of business on December 31, 2024.

07:31 EST Hesai announces exclusive lidar design win with Great Wall Motor - Hesai announced an exclusive series production design win with Great Wall Motor, covering several models across its two brands. These models will feature Hesai's ATX, an ultra-compact high-resolution long-range lidar, scheduled for mass production starting in 2025. Great Wall Motor, an automotive manufacturer in China, has made significant leaps in new energy and intelligent technologies, achieving significant milestones in intelligent driving and smart cockpit systems. In 2023, the company sold over 1.23M vehicles, including a record 262,000 electric vehicles. In the first three quarters of 2024, sales of Great Wall Motor EVs reached 195,000, reflecting a robust 57.2% year-over-year growth.

07:23 EST Newmont to sell CC&V operation to SSR Mining for up to $275M in cash - Newmont (NEM) announced that it has agreed to sell its Cripple Creek & Victor, or CC&V, operation in Colorado to SSR Mining (SSRM) for up to $275M in cash consideration. Upon closing the announced transactions, Newmont will have delivered up to $3.9B in gross proceeds from non-core asset divestitures and investment sales. The transaction is expected to close in the first quarter of 2025, subject to certain conditions being satisfied. Under the terms of the agreement, Newmont expects to receive gross proceeds of up to $275M, which includes: cash consideration of $100M, due upon closing deferred contingent cash consideration of $87.5M upon receipt of pending regulatory approvals; deferred contingent cash consideration of $87.5M upon resolution of regulatory applications relating to the Carlton Tunnel. Upon completion of an updated regulator-approved closure plan and in the event aggregate closure costs at CC&V exceed $500M, Newmont will be responsible for funding 90% of the incremental closure costs in such updated closure plan, either on an as-incurred basis or pursuant to a net present value lump sum payment option.

07:18 EST SMX, Ybrya Capital announce heads of agreement, setting stage for merger - SMX and Ybyra Capital signed a non-binding Heads of Agreement. This Heads of Agreement sets the initial foundation for a potentially transformative merger, which upon completion would combine SMX's advanced digital platform traceability technologies with Ybyra's asset base and operational infrastructure, to create synergies to drive transparent and accountable global trade. The merger, as contemplated in the Heads of Agreement and approved in principle by Ybyra Capital's shareholders on 5 December 2024, sets forth a strategic framework expected to position SMX to leverage synergies and expand into untapped high-growth markets. Key Highlights of the Heads of Agreement: Asset Contribution and Valuation- Ybyra Capital will contribute certain fertilizer holdings, real estate assets and other assets in Brazil to a newly created Irish private company wholly owned by SMX. An independent appraiser will establish the valuation of these assets. Share Swap Structure- Ybyra shareholders will receive shares in SMX in exchange for the contributed assets. Definitive Shareholder Meeting- SMX and Ybyra will each call a special shareholder meeting to approve the transactions, after finalizing definitive and binding agreements. Projected Completion Date- The parties are targeting the first half of 2025 to close the merger. The merger is expected to allow the harnessing of SMX's expertise known as "material efficiency" and "equilibrium effect" in marking, tracking, and certifying the authenticity and provenance of products such as coffee, tea, metals, palm oil, and natural rubber. These capabilities will integrate with Ybyra Capital's logistics and commodity infrastructure-including fertilizer facilities-enabling rapid scaling of SMX's traceability solutions across South America and Asia. SMX's scalable technology, after deployment across Ybyra's logistics network, is expected to be then expanded into operations across South America and Asia, unlocking exponential growth potential. The combined entity further intends to set new standards in sustainable and ethical certification for commodities traded between South America and the United States, targeting evolving market demands and global sustainability goals in those regions. The non-binding Heads of Agreement provides a roadmap, including the need for further due diligence, regulatory and shareholder approvals, and drafting of definitive merger documents. The parties cannot at this time give any assurance that definitive documents will be executed or delivered, that both companies will satisfy all expected closing conditions, including stockholder approvals, or that the transaction will ever be consummated.

07:06 EST NextSource Materials announces results of annual meeting - NextSource Materials announced the results of the Annual Meeting of Shareholders of the Company held virtually at 9:00 AM on December 5, 2024. Election of Directors. The Company's shareholders elected each of the nominees as directors to serve until the next annual meeting of shareholders, or until their respective successors are elected or appointed. The Company's shareholders approved the appointment of PricewaterhouseCoopers, Chartered Professional Accountants, as the Company's auditors for the fiscal year ending June 30, 2025 and that the Board of Directors is authorized to fix their remuneration

07:01 EST Beam Therapeutics appoints Sravan Emany as CFO - Beam Therapeutics (BEAM) announced the appointment of Sravan Emany as CFO, effective December 19, 2024. He most recently served as CFO and COO at Ironwood Pharmaceuticals (IRWD)

06:58 EST SSR Mining acquires Cripple Creek & Victor Gold Mine from Newmont - SSR Mining (SSR) is pleased to announce that it has entered into a definitive purchase agreement to acquire the Cripple Creek & Victor Gold Mine in Colorado from Newmont (NEM) in an all-cash deal for $100M in upfront consideration and up to $175M in additional milestone-based payments. CC&V is expected to add approximately 170,000 ounces in annual gold production to SSR Mining's platform and, combined with Marigold, the company's total U.S. gold production is expected to average between 300,000-400,000 ounces annually. The Transaction is expected to close in the first quarter of 2025, upon satisfaction of preclosing conditions and the receipt of all required regulatory approvals.

06:35 EST Ault & Company to commence Dutch Tender offer for shares of Hyperscale Data - Ault & Company announced that it intends to initiate a cash tender offer to purchase up to 111,000 shares of Class A common stock of Hyperscale Data at a price not greater than $10.00 nor less than $7.50 per share of common stock, net to the seller in cash, less any applicable withholding taxes and without interest. The exact price will be determined through a modified Dutch auction described in the offering materials to be filed with the SEC upon commencement of the offer. The offer is expected to commence in late December 2024 or early January 2025 and is subject to Ault & Company board approval, regulatory approval and other customary closing conditions.

06:31 EST TRX Gold names Richard Boffey as COO - TRX Gold is pleased to announce the appointment of Richard Boffey as COO, effective immediately. Boffey is a seasoned executive, bringing more than 35 years of operational experience to the TRX Gold team and will be instrumental in the continued growth and development of Buckreef Gold. Boffey joins TRX Gold having previously held senior executive positions with other multi-national mining companies. Most recently, he held the position of General / Country Manager at the Tara Resources Brskovo Mine Project in Montenegro.

06:01 EST Novartis reports new Phase 3B data for Fabhalta - Novartis announced positive topline results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of twice-daily oral monotherapy Fabhalta in adult patients with paroxysmal nocturnal hemoglobinuria who were switched from anti-C5 therapies. After 24 weeks of treatment with Fabhalta, the average Hb level improved versus baseline. In the study, the safety profile of Fabhalta monotherapy was consistent with previously reported data. "These new results add to the body of evidence reinforcing that Fabhalta can benefit both patients previously treated with anti-C5 therapies studied in the APPULSE-PNH and APPLY-PNH trials and complement-inhibitor naive patients studied in the APPOINT-PNH trial," said Antonio Risitano, M.D., Ph.D., Chair of the International PNH Interest Group and Head of the Hematology and Hematopoietic Transplant Unit, Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria at the AORN San Giuseppe Moscati, Avellino, Italy, and APPULSE-PNH trial lead investigator. "Treatment goals for patients with PNH have greatly evolved, and we can now aim to resolve signs and symptoms of disease in most patients. It is promising to see this evolution, and we will continue to make progress to best support these patients."

05:37 EST Trump names David Sacks 'White House AI & Crypto Czar' - President-elect Donald Trump announced that David O. Sacks will be the "White House A.I. & Crypto Czar." He said: "n this important role, David will guide policy for the Administration in Artificial Intelligence and Cryptocurrency, two areas critical to the future of American competitiveness. David will focus on making America the clear global leader in both areas. He will safeguard Free Speech online, and steer us away from Big Tech bias and censorship. He will work on a legal framework so the Crypto industry has the clarity it has been asking for, and can thrive in the U.S. David will also lead the Presidential Council of Advisors for Science and Technology... David has the knowledge, business experience, intelligence, and pragmatism to MAKE AMERICA GREAT in these two critical technologies. Congratulations, David!" Publicly traded companies in the space include Bit Digital (BTBT), Bitfarms (BITF), Coinbase (COIN), Core Scientific (CORZ), Greenidge Generation (GREE), Mara Holdings (MARA), MicroStrategy (MSTR), Riot Platforms (RIOT), Stronghold Digital Mining (SDIG) and TeraWulf (WULF). Reference Link

05:12 EST Innate Pharma partners with IFLI to study IPH6501, to receive $3M upfront - Innate Pharma with the Institute for Follicular Lymphoma, or IFLI, announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate's anti-CD20 Anket in follicular lymphoma , or FL. Innate's ongoing Phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501 in patients with relapsed and/or refractory CD20-expressing Non-Hodgkin Lymphoma will also include patients with relapsed / refractory FL. To support the Phase 1/2 trial and inclusion of FL patients, IFLI will initially invest $3M into new shares of Innate, issued through a capital increase reserved to IFLI at a price of EUR 1.56 per share and representing 2.26% of the share capital of Innate. IFLI may also invest up to an additional $4.9M into new shares of Innate, depending on the completion of certain milestones, at a price to be determined at the time of the said investments.